Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerard Lozanski

Showing results (41-50 of 134) with videos related to

Pageof 14
Sort By:
The New England Journal of Medicine|September 7, 2022
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 SubvariantsPanke Qu, Julia N Faraone, John P Evans, et al.
Leukemia & Lymphoma|February 29, 2012
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B studyGerard Lozanski, Amy S Ruppert, Nyla A Heerema, et al.
Leukemia & Lymphoma|March 6, 2009
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphomaKristie A Blum, Mehdi Hamadani, Gary S Phillips, et al.
American Journal of Hematology|February 22, 2023
Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysisNarendranath Epperla, Qiuhong Zhao, Mirela Anghelina, et al.
Plos One|April 3, 2010
Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activityAndrzej T Slominski, Zorica Janjetovic, Brian E Fuller, et al.
Blood Advances|February 24, 2023
Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawalMark B Geyer, Brian C Shaffer, Bhavana Bhatnagar, et al.
Blood|January 17, 2004
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsGerard Lozanski, Nyla A Heerema, Ian W Flinn, et al.
JCI Insight|October 9, 2020
Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donorsCong Zeng, John P Evans, Rebecca Pearson, et al.
Medrxiv : the Preprint Server for Health Sciences|August 15, 2020
Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assayCong Zeng, John P Evans, Rebecca Pearson, et al.
Haematologica|October 30, 2020
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, et al.
Pageof 14

Showing results (41-50 of 134) with videos related to

Sort By:
Pageof 14
The New England Journal of Medicine|September 7, 2022
Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 SubvariantsPanke Qu, Julia N Faraone, John P Evans, et al.
Leukemia & Lymphoma|February 29, 2012
Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B studyGerard Lozanski, Amy S Ruppert, Nyla A Heerema, et al.
Leukemia & Lymphoma|March 6, 2009
Prolonged myelosuppression with clofarabine in the treatment of patients with relapsed or refractory, aggressive non-Hodgkin lymphomaKristie A Blum, Mehdi Hamadani, Gary S Phillips, et al.
American Journal of Hematology|February 22, 2023
Impact of sex on outcomes in patients with hairy cell leukemia. An HCL patient data registry analysisNarendranath Epperla, Qiuhong Zhao, Mirela Anghelina, et al.
Plos One|April 3, 2010
Products of vitamin D3 or 7-dehydrocholesterol metabolism by cytochrome P450scc show anti-leukemia effects, having low or absent calcemic activityAndrzej T Slominski, Zorica Janjetovic, Brian E Fuller, et al.
Blood Advances|February 24, 2023
Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawalMark B Geyer, Brian C Shaffer, Bhavana Bhatnagar, et al.
Blood|January 17, 2004
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletionsGerard Lozanski, Nyla A Heerema, Ian W Flinn, et al.
JCI Insight|October 9, 2020
Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers, and convalescent plasma donorsCong Zeng, John P Evans, Rebecca Pearson, et al.
Medrxiv : the Preprint Server for Health Sciences|August 15, 2020
Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assayCong Zeng, John P Evans, Rebecca Pearson, et al.
Haematologica|October 30, 2020
Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase 1b study (GO28440)Stephan Stilgenbauer, Franck Morschhauser, Clemens-Martin Wendtner, et al.
Pageof 14